Non-lithium treatment for bipolar disorder.

Area of Science:

• Psychiatry
• Pharmacology

Background:

• Lithium carbonate is the primary treatment for bipolar disorder.
• A significant percentage of patients (20-40%) show inadequate response to lithium.
• Adjunctive therapies may worsen the illness's subsequent phases.

Purpose of the Study:

• To evaluate the efficacy of alternative treatments for bipolar disorder.
• To examine the role of anticonvulsants in managing bipolar illness.
• To review emerging therapeutic options beyond lithium.

Main Methods:

• Review of controlled and uncontrolled studies on carbamazepine in bipolar disorder.
• Analysis of response rates in patients treated with carbamazepine, alone or with lithium.
• Evaluation of antimanic and antidepressant effects of carbamazepine.
• Inclusion of data on other anticonvulsants (valproate), benzodiazepines (clonazepam), and calcium channel blockers (verapamil).

Main Results:

• Carbamazepine demonstrated a response rate of approximately 65% in over 500 patients.
• Antimanic effects of carbamazepine are established, but antidepressant effects require further investigation.
• Other anticonvulsants like valproate appear effective.

Conclusions:

• Carbamazepine is a promising alternative or adjunct for bipolar disorder management, particularly for patients unresponsive to lithium.
• Further research is needed to fully understand carbamazepine's antidepressant properties.
• Valproate and other agents are also under investigation for bipolar disorder treatment.